Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 3004 results

Press release / Oct 07, 2026

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible…
Press release / Oct 07, 2026

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and…
Story / Oct 07, 2026

The patient who changed the course of my career

People and Culture

Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.
Clinical Trials / Oct 05, 2026

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Clinical Trials / Oct 02, 2026

Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Event / Feb 03, 2027

Novartis 2026 Financial Results

Novartis announces the company’s fourth quarter and 2026 full year financial results.
Event / Jan 11, 2027

J.P. Morgan Healthcare Conference
Event / Dec 09, 2026

Deutsche Bank C-Suite call series
Event / Dec 07, 2026

Bank of America R&D call series
Event / Dec 01, 2026

Citi Global Healthcare Conference